TXMD Logo

TherapeuticsMD, Inc. (TXMD) 

NASDAQ
Market Cap
$12.69M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
395 of 960
Rank in Industry
21 of 59

Largest Insider Buys in Sector

TXMD Stock Price History Chart

TXMD Stock Performance

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and …

Insider Activity of TherapeuticsMD, Inc.

Over the last 12 months, insiders at TherapeuticsMD, Inc. have bought $9,138 and sold $0 worth of TherapeuticsMD, Inc. stock.

On average, over the past 5 years, insiders at TherapeuticsMD, Inc. have bought $7.08M and sold $9.93M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Collins Cooper C. (director) — $9,138.

The last purchase of 4,094 shares for transaction amount of $7,099 was made by Collins Cooper C. (director) on 2024‑08‑22.

List of Insider Buy and Sell Transactions, TherapeuticsMD, Inc.

2024-08-22Purchasedirector
4,094
0.0352%
$1.73$7,099-9.71%
2024-08-21Purchasedirector
1,200
0.0105%
$1.70$2,039-6.51%
2023-12-07SaleChief Executive Officer
4,550
0.0421%
$2.24$10,187-11.67%
2023-12-06SaleChief Executive Officer
14,500
0.1412%
$2.31$33,496-10.62%
2023-04-26SaleChief Executive Officer
692
0.0079%
$3.64$2,518-25.21%
2023-04-12SaleChief Executive Officer
1,170
0.013%
$3.65$4,276-23.69%
2023-01-27SalePrin. Fin. and Acctg. Officer
49
0.0005%
$5.09$249-30.90%
2023-01-26SalePrin. Fin. and Acctg. Officer
1,648
0.0183%
$5.08$8,371-27.36%
2023-01-24SalePrin. Fin. and Acctg. Officer
7
<0.0001%
$5.31$37-29.48%
2023-01-23SalePrin. Fin. and Acctg. Officer
1,302
0.0145%
$5.34$6,950-30.45%
2022-12-30Saledirector
29,000
$1,333.00$38.66M-31.84%
2022-12-09SaleCo-Chief Executive Officer
320
0.0035%
$6.31$2,020-39.72%
2022-12-09Purchasedirector
14,825
0.1558%
$6.09$90,284-39.72%
2022-12-08Purchasedirector
300
0.0032%
$5.83$1,749-35.20%
2022-12-07Saledirector
3,922
0.038%
$5.26$20,635-35.44%
2022-12-07Purchasedirector
20,113
0.2099%
$5.66$113,890-35.44%
2022-12-06SaleGeneral Counsel
1,048
0.0106%
$4.95$5,185-28.06%
2022-12-06SaleInterim CFO/CAO/VP of Finance
910
0.0089%
$4.78$4,345-28.06%
2022-12-06SaleCo-Chief Executive Officer
935
0.0094%
$4.92$4,602-28.06%
2022-12-06SaleCo-Chief Executive Officer
440
0.0044%
$4.92$2,165-28.06%

Insider Historical Profitability

<0.0001%
Collins Cooper C.director
52016
0.451%
$1.1091<0.0001%
Finizio Robert GCEO
17991637
156.0095%
$1.10524<0.0001%
Milligan John C.K. IVSecretary/CEO of subsidiary
1752703
15.1981%
$1.10324<0.0001%
Thompson Tommy Gdirector
715600
6.2051%
$1.10130<0.0001%
C.S. Finance LLC
357606
3.1009%
$1.1010

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Helm Capital Management LLC$2.73M10.341.19M0%+$00.08
Clearline Capital LP$1.23M4.64535,340+14.83%+$158,305.460.12
Tejara Capital Ltd$920,436.003.49401,9370%+$00.31
The Vanguard Group$887,563.003.36387,5820%+$0<0.0001
BlackRock$310,934.001.18135,779-0.35%-$1,108.36<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.